Proathlete Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$444K Buy
383
+151
+65% +$178K 0.1% 54
2026
Q2
$279K Hold
232
– – 0.07% 56
2026
Q1
$214K Buy
232
+63
+37% +$63.9K 0.06% 61
2025
Q4
$182K Hold
169
– – 0.05% 69
2025
Q3
$129K Sell
169
-3
-2% -$2.23K 0.04% 82
2025
Q2
$134K Buy
172
+45
+35% +$35K 0.04% 74
2025
Q1
$105K Buy
+127
New +$106K 0.04% 87

Other funds holding LLY

Proathlete Wealth Management's LLY Position: Q3 2026 in Review

Proathlete Wealth Management increased its Eli Lilly (LLY) stake by 65% in Q3 2026, buying an estimated $178K and bringing the position to 383 shares worth $444K. The position accounts for 0.1% of the portfolio, ranked #54.

Proathlete Wealth Management first reported a position in LLY in Q1 2025 and has held it in 7 quarters since. 1,509 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Proathlete Wealth Management held 383 shares of Eli Lilly worth $444K as of Q3 2026.
  • Proathlete Wealth Management bought 151 Eli Lilly shares in Q3 2026, an estimated $178K.
  • Eli Lilly made up 0.1% of Proathlete Wealth Management's portfolio in Q3 2026, its #54 holding.
  • Proathlete Wealth Management first reported a position in Eli Lilly in Q1 2025 and has held it in 7 quarters since.
  • 1,509 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Proathlete Wealth Management's 13F filing for Q3 2026, filed 15 Oct 2026.